<DOC>
	<DOCNO>NCT02210663</DOCNO>
	<brief_summary>This Phase 1 study evaluate tolerability , safety , pharmacokinetics preliminary efficacy single agent Veliparib Japanese subject advance solid tumor .</brief_summary>
	<brief_title>A Phase 1 Study Single Agent Veliparib Japanese Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Veliparib</mesh_term>
	<criteria>Histologically cytologically confirm malignant solid tumor , follow : * Subjects recurrent high grade serous ovarian cancer complete discontinue platinum base therapy ; * Subjects BRCAmutated breast cancer receive prior chemotherapy anthracycline and/or taxanes ; * Subjects deleterious mutation BRCA advance solid tumor receive available standard therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . Life expectancy great 12 week . Adequate organ marrow functionÂ· Measurable nonmeasurable disease . Major surgery and/or radiation within ( &lt; ) 4 week prior study enrollment . Chemotherapy hormone therapy within ( &lt; ) 4 week prior study enrollment except mitomycin C nitrosoureas , case 6 week . Any investigational agent within ( &lt; ) 4 week prior study enrollment . Any anticancer Chinese medicine/herbal remedy within 14 day prior study enrollment . Toxicities ( exception alopecia ) prior major surgery , radiation , systemic chemotherapy recover less grade 2 .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>PARP</keyword>
	<keyword>Primary peritoneal cancer</keyword>
	<keyword>Fallopian tube</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>veliparib</keyword>
	<keyword>ABT-888</keyword>
	<keyword>BRCA</keyword>
</DOC>